drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB08871 | DB08895 | 36 | 976 | [
"DDInter666",
"DDInter1825"
] | Eribulin | Tofacitinib | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
36,
25,
976
]
],
[
[
36,
63,
1461
],
[
1461,
23,
976
]
],
[
[
36,
24,
214
],
[
214,
63,
976
]
],
[
[
36,
25,
982
],
[
982,
63,
... | [
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatini... |
DB00421 | DB01017 | 443 | 1,669 | [
"DDInter1707",
"DDInter1224"
] | Spironolactone | Minocycline | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Minor | 0 | [
[
[
443,
23,
1669
]
],
[
[
443,
23,
1572
],
[
1572,
1,
1669
]
],
[
[
443,
62,
964
],
[
964,
1,
1669
]
],
[
[
443,
23,
1545
],
[
1545,
... | [
[
[
"Spironolactone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Spironolactone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],... | Spironolactone may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Spironolactone may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Minocyc... |
DB08816 | DB11979 | 578 | 1,320 | [
"DDInter1802",
"DDInter625"
] | Ticagrelor | Elagolix | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
578,
24,
1320
]
],
[
[
578,
23,
271
],
[
271,
23,
1320
]
],
[
[
578,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
578,
63,
79
],
[
79,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrost... |
DB08867 | DB11691 | 807 | 1,499 | [
"DDInter1897",
"DDInter1258"
] | Ulipristal | Naldemedine | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
807,
24,
1499
]
],
[
[
807,
62,
723
],
[
723,
24,
1499
]
],
[
[
807,
24,
98
],
[
98,
24,
1499
]
],
[
[
807,
63,
578
],
[
578,
24... | [
[
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ulipristal",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
... | Ulipristal may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem ... |
DB00497 | DB11569 | 828 | 1,093 | [
"DDInter1366",
"DDInter1003"
] | Oxycodone | Ixekizumab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
828,
24,
1093
]
],
[
[
828,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
828,
63,
58
],
[
58,
24,
1093
]
],
[
[
828,
63,
1057
],
[
1057,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Aleface... |
DB00491 | DB00816 | 127 | 1,674 | [
"DDInter1217",
"DDInter1346"
] | Miglitol | Orciprenaline | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
127,
24,
1674
]
],
[
[
127,
24,
874
],
[
874,
24,
1674
]
],
[
[
127,
63,
1636
],
[
1636,
24,
1674
]
],
[
[
127,
21,
28809
],
[
28809,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Ph... |
DB00247 | DB00446 | 1,131 | 597 | [
"DDInter1194",
"DDInter351"
] | Methysergide | Chloramphenicol | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
1131,
24,
597
]
],
[
[
1131,
21,
28787
],
[
28787,
60,
597
]
],
[
[
1131,
24,
1101
],
[
1101,
23,
597
]
],
[
[
1131,
24,
159
],
[
159,... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effe... | Methysergide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chloramphenicol (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken wit... |
DB00501 | DB01125 | 752 | 279 | [
"DDInter380",
"DDInter98"
] | Cimetidine | Anisindione | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
752,
24,
279
]
],
[
[
752,
24,
467
],
[
467,
23,
279
]
],
[
[
752,
24,
1195
],
[
1195,
24,
279
]
],
[
[
752,
63,
883
],
[
883,
2... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Anisindione
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erloti... |
DB00047 | DB14276 | 176 | 1,631 | [
"DDInter932",
"DDInter1892"
] | Insulin glargine | Turmeric | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
176,
24,
1631
]
],
[
[
176,
24,
1479
],
[
1479,
23,
1631
]
],
[
[
176,
24,
1281
],
[
1281,
24,
1631
]
],
[
[
176,
24,
1479
],
[
1479,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic a... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Turmeric
Insulin glargine may cause a moderate interaction that could exacerbate diseases when take... |
DB00250 | DB09121 | 10 | 1,328 | [
"DDInter475",
"DDInter140"
] | Dapsone | Aurothioglucose | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
10,
24,
1328
]
],
[
[
10,
63,
367
],
[
367,
24,
1328
]
],
[
[
10,
24,
310
],
[
310,
24,
1328
]
],
[
[
10,
24,
270
],
[
270,
63,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Ca... |
DB00011 | DB14783 | 1,451 | 287 | [
"DDInter944",
"DDInter574"
] | Interferon alfa-n1 | Diroximel fumarate | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1451,
24,
287
]
],
[
[
1451,
25,
1101
],
[
1101,
24,
287
]
],
[
[
1451,
24,
1560
],
[
1560,
24,
287
]
],
[
[
1451,
23,
450
],
[
450,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],... | Interferon alfa-n1 may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase... |
DB00367 | DB06335 | 566 | 761 | [
"DDInter1061",
"DDInter1646"
] | Levonorgestrel | Saxagliptin | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
566,
24,
761
]
],
[
[
566,
6,
8374
],
[
8374,
45,
761
]
],
[
[
566,
21,
28966
],
[
28966,
60,
761
]
],
[
[
566,
24,
1296
],
[
1296,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Levonorgestrel (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Levonorgestrel may cause a moderate interaction that... |
DB14520 | DB14550 | 1,229 | 821 | [
"DDInter1785",
"DDInter803"
] | Tetraferric tricitrate decahydrate | Gallium chloride Ga-67 | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Gallium chloride Ga-67 is the chloride salt of a gallium radioisotope which is typically complexed with [sodium citrate] to generate [gallium citrate Ga 67], which can be used to image certain cancers and inflammatory lesions. | Moderate | 1 | [
[
[
1229,
24,
821
]
],
[
[
1229,
63,
1299
],
[
1299,
63,
663
],
[
663,
24,
821
]
],
[
[
1229,
63,
1299
],
[
1299,
25,
1220
],
[
1220,
24... | [
[
[
"Tetraferric tricitrate decahydrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gallium chloride Ga-67"
]
],
[
[
"Tetraferric tricitrate decahydrate",
"{u} may cause a moderate interaction that could exacerbate disea... | Tetraferric tricitrate decahydrate may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases... |
DB00916 | DB09276 | 112 | 381 | [
"DDInter1202",
"DDInter1682"
] | Metronidazole | Sodium aurothiomalate | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Moderate | 1 | [
[
[
112,
24,
381
]
],
[
[
112,
63,
491
],
[
491,
24,
381
]
],
[
[
112,
24,
1047
],
[
1047,
24,
381
]
],
[
[
112,
24,
1480
],
[
1480,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterfe... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Metronidazole may cause a moderate interaction that could exacerbate disease... |
DB00465 | DB11921 | 886 | 1,019 | [
"DDInter1010",
"DDInter492"
] | Ketorolac | Deflazacort | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
886,
24,
1019
]
],
[
[
886,
24,
959
],
[
959,
24,
1019
]
],
[
[
886,
25,
629
],
[
629,
24,
1019
]
],
[
[
886,
24,
877
],
[
877,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Ketorolac may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a mod... |
DB00341 | DB00408 | 1,242 | 1,408 | [
"DDInter343",
"DDInter1099"
] | Cetirizine | Loxapine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | An antipsychotic agent used in schizophrenia. [PubChem] | Moderate | 1 | [
[
[
1242,
24,
1408
]
],
[
[
1242,
24,
902
],
[
902,
40,
1408
]
],
[
[
1242,
24,
1119
],
[
1119,
1,
1408
]
],
[
[
1242,
35,
623
],
[
623,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loxapine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Loxapine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Loxapine (Compou... |
DB00238 | DB09065 | 188 | 760 | [
"DDInter1285",
"DDInter424"
] | Nevirapine | Cobicistat | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
188,
24,
760
]
],
[
[
188,
23,
1101
],
[
1101,
23,
760
]
],
[
[
188,
24,
1374
],
[
1374,
23,
760
]
],
[
[
188,
24,
1041
],
[
1041,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiratero... |
DB00041 | DB00678 | 1,648 | 240 | [
"DDInter38",
"DDInter1095"
] | Aldesleukin | Losartan | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Moderate | 1 | [
[
[
1648,
24,
240
]
],
[
[
1648,
24,
1414
],
[
1414,
1,
240
]
],
[
[
1648,
24,
911
],
[
911,
40,
240
]
],
[
[
1648,
25,
593
],
[
593,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan and Eprosartan (Compound) resembles Losartan (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Lo... |
DB01004 | DB09052 | 563 | 250 | [
"DDInter806",
"DDInter220"
] | Ganciclovir | Blinatumomab | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
563,
24,
250
]
],
[
[
563,
24,
1362
],
[
1362,
63,
250
]
],
[
[
563,
63,
305
],
[
305,
24,
250
]
],
[
[
563,
24,
869
],
[
869,
2... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escheric... |
DB00270 | DB06791 | 1,428 | 1,446 | [
"DDInter993",
"DDInter1021"
] | Isradipine | Lanreotide | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
1428,
24,
1446
]
],
[
[
1428,
24,
1017
],
[
1017,
63,
1446
]
],
[
[
1428,
1,
1081
],
[
1081,
24,
1446
]
],
[
[
1428,
24,
549
],
[
549,... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Isradipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that cou... |
DB00342 | DB01118 | 1,181 | 33 | [
"DDInter1770",
"DDInter76"
] | Terfenadine | Amiodarone | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
1181,
25,
33
]
],
[
[
1181,
25,
540
],
[
540,
1,
33
]
],
[
[
1181,
24,
1419
],
[
1419,
24,
33
]
],
[
[
1181,
24,
1476
],
[
1476,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{... | Terfenadine may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate dis... |
DB00975 | DB11703 | 1,317 | 405 | [
"DDInter573",
"DDInter9"
] | Dipyridamole | Acalabrutinib | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1317,
25,
405
]
],
[
[
1317,
63,
383
],
[
383,
24,
405
]
],
[
[
1317,
24,
643
],
[
643,
24,
405
]
],
[
[
1317,
24,
738
],
[
738,
... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken... |
DB01229 | DB06273 | 973 | 980 | [
"DDInter1378",
"DDInter1824"
] | Paclitaxel (protein-bound) | Tocilizumab | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
973,
24,
980
]
],
[
[
973,
63,
1461
],
[
1461,
23,
980
]
],
[
[
973,
63,
139
],
[
139,
24,
980
]
],
[
[
973,
24,
309
],
[
309,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Paclitaxel m... |
DB00569 | DB05578 | 553 | 330 | [
"DDInter775",
"DDInter1566"
] | Fondaparinux | Ramucirumab | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
553,
25,
330
]
],
[
[
553,
24,
41
],
[
41,
63,
330
]
],
[
[
553,
24,
901
],
[
901,
24,
330
]
],
[
[
553,
63,
1100
],
[
1100,
24,... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"... | Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Milnac... |
DB00647 | DB04951 | 675 | 187 | [
"DDInter528",
"DDInter1477"
] | Dextropropoxyphene | Pirfenidone | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
675,
24,
187
]
],
[
[
675,
25,
1670
],
[
1670,
63,
187
]
],
[
[
675,
64,
702
],
[
702,
24,
187
]
],
[
[
675,
24,
1045
],
[
1045,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
... | Dextropropoxyphene may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Dextropropoxyphene may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may caus... |
DB00280 | DB09134 | 494 | 1,552 | [
"DDInter575",
"DDInter966"
] | Disopyramide | Ioversol | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Moderate | 1 | [
[
[
494,
24,
1552
]
],
[
[
494,
24,
589
],
[
589,
25,
1552
]
],
[
[
494,
25,
485
],
[
485,
25,
1552
]
],
[
[
494,
24,
589
],
[
589,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Ioversol
Disopyramide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major lif... |
DB01033 | DB10795 | 328 | 221 | [
"DDInter1156",
"DDInter1486"
] | Mercaptopurine | Poliovirus type 1 antigen (formaldehyde inactivated) | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
328,
24,
221
]
],
[
[
328,
64,
581
],
[
581,
24,
221
]
],
[
[
328,
63,
599
],
[
599,
24,
221
]
],
[
[
328,
24,
384
],
[
384,
24,... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",... | Mercaptopurine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mercaptopurine may cause a moderate interaction that could exacerbate diseases wh... |
DB00488 | DB08895 | 196 | 976 | [
"DDInter57",
"DDInter1825"
] | Altretamine | Tofacitinib | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
196,
25,
976
]
],
[
[
196,
63,
1461
],
[
1461,
23,
976
]
],
[
[
196,
24,
200
],
[
200,
63,
976
]
],
[
[
196,
24,
1430
],
[
1430,
... | [
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and C... |
DB01076 | DB06317 | 700 | 1,626 | [
"DDInter133",
"DDInter630"
] | Atorvastatin | Elotuzumab | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
700,
24,
1626
]
],
[
[
700,
24,
973
],
[
973,
24,
1626
]
],
[
[
700,
63,
597
],
[
597,
24,
1626
]
],
[
[
700,
40,
671
],
[
671,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol a... |
DB00635 | DB00685 | 1,573 | 1,299 | [
"DDInter1515",
"DDInter1887"
] | Prednisone | Trovafloxacin | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Major | 2 | [
[
[
1573,
25,
1299
]
],
[
[
1573,
25,
872
],
[
872,
40,
1299
]
],
[
[
1573,
64,
1467
],
[
1467,
40,
1299
]
],
[
[
1573,
21,
29093
],
[
290... | [
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
... | Prednisone may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Prednisone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Trovafloxacin (Compound)
Prednisone (Compound) ca... |
DB00872 | DB01229 | 1,080 | 973 | [
"DDInter438",
"DDInter1378"
] | Conivaptan | Paclitaxel (protein-bound) | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
1080,
24,
973
]
],
[
[
1080,
24,
310
],
[
310,
63,
973
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
973
]
],
[
[
1080,
21,
28779
],
[
28779,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Conivapt... |
DB00108 | DB14761 | 1,066 | 242 | [
"DDInter1268",
"DDInter1578"
] | Natalizumab | Remdesivir | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1066,
24,
242
]
],
[
[
1066,
25,
1377
],
[
1377,
24,
242
]
],
[
[
1066,
64,
367
],
[
367,
24,
242
]
],
[
[
1066,
24,
267
],
[
267,
... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Lefluno... | Natalizumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Natalizumab may lead to a major life threatening interaction when taken with Interferon alfacon-1 and Interferon alfacon-1 m... |
DB01225 | DB14276 | 500 | 1,631 | [
"DDInter645",
"DDInter1892"
] | Enoxaparin | Turmeric | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
500,
23,
1631
]
],
[
[
500,
64,
20
],
[
20,
23,
1631
]
],
[
[
500,
25,
1046
],
[
1046,
23,
1631
]
],
[
[
500,
64,
20
],
[
20,
24... | [
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase... | Enoxaparin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Enoxaparin may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a minor int... |
DB00762 | DB08881 | 613 | 868 | [
"DDInter973",
"DDInter1925"
] | Irinotecan | Vemurafenib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
613,
24,
868
]
],
[
[
613,
6,
8374
],
[
8374,
45,
868
]
],
[
[
613,
7,
3361
],
[
3361,
46,
868
]
],
[
[
613,
18,
16717
],
[
16717,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Irinotecan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Irinotecan (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Vemurafenib (Compound)
Irinotecan (Compound) downregulates KAT6B (Gene) and KAT6B (Gene) is upregulated by Vemurafenib (Compound)
Irinotecan (C... |
DB00176 | DB08896 | 529 | 292 | [
"DDInter770",
"DDInter1576"
] | Fluvoxamine | Regorafenib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
529,
24,
292
]
],
[
[
529,
6,
6017
],
[
6017,
45,
292
]
],
[
[
529,
21,
28890
],
[
28890,
60,
292
]
],
[
[
529,
23,
1135
],
[
1135,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound... | Fluvoxamine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Fluvoxamine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Fluvoxamine may cause a minor interaction that can limit clinical effects when tak... |
DB00163 | DB06754 | 1,461 | 707 | [
"DDInter1943",
"DDInter471"
] | Vitamin E | Danaparoid | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
1461,
24,
707
]
],
[
[
1461,
24,
298
],
[
298,
63,
707
]
],
[
[
1461,
24,
235
],
[
235,
64,
707
]
],
[
[
1461,
24,
291
],
[
291,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin m... |
DB00363 | DB06292 | 695 | 549 | [
"DDInter419",
"DDInter474"
] | Clozapine | Dapagliflozin | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
695,
24,
549
]
],
[
[
695,
24,
1344
],
[
1344,
40,
549
]
],
[
[
695,
6,
9842
],
[
9842,
45,
549
]
],
[
[
695,
25,
79
],
[
79,
23... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Clozapine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Clozapine may lead to a major life threatening interacti... |
DB00065 | DB00688 | 581 | 955 | [
"DDInter923",
"DDInter1251"
] | Infliximab | Mycophenolate mofetil | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Major | 2 | [
[
[
581,
25,
955
]
],
[
[
581,
25,
1096
],
[
1096,
40,
955
]
],
[
[
581,
23,
1114
],
[
1114,
62,
955
]
],
[
[
581,
24,
1031
],
[
1031,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophe... | Infliximab may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction t... |
DB00781 | DB09134 | 1,481 | 1,552 | [
"DDInter1489",
"DDInter966"
] | Polymyxin B | Ioversol | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1481,
25,
1552
]
],
[
[
1481,
24,
242
],
[
242,
63,
1552
]
],
[
[
1481,
25,
1448
],
[
1448,
25,
1552
]
],
[
[
1481,
63,
963
],
[
963,
... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir... | Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Polymyxin B may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may le... |
DB00188 | DB09045 | 168 | 52 | [
"DDInter222",
"DDInter607"
] | Bortezomib | Dulaglutide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
168,
24,
52
]
],
[
[
168,
24,
170
],
[
170,
23,
52
]
],
[
[
168,
24,
609
],
[
609,
24,
52
]
],
[
[
168,
24,
1412
],
[
1412,
63,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and C... |
DB00485 | DB00682 | 916 | 126 | [
"DDInter541",
"DDInter1951"
] | Dicloxacillin | Warfarin | One of the penicillins which is resistant to penicillinase. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
916,
25,
126
]
],
[
[
916,
6,
8374
],
[
8374,
45,
126
]
],
[
[
916,
25,
663
],
[
663,
23,
126
]
],
[
[
916,
1,
1390
],
[
1390,
6... | [
[
[
"Dicloxacillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Dicloxacillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"War... | Dicloxacillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Warfarin (Compound)
Dicloxacillin may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Dicloxacillin (Compound) rese... |
DB00827 | DB06203 | 646 | 1,002 | [
"DDInter383",
"DDInter51"
] | Cinoxacin | Alogliptin | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
646,
24,
1002
]
],
[
[
646,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
646,
21,
29340
],
[
29340,
60,
1002
]
],
[
[
646,
64,
176
],
[
176,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Cinoxacin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Alogliptin (Compound)
Cinoxacin may ... |
DB00402 | DB08912 | 1,407 | 1,040 | [
"DDInter685",
"DDInter462"
] | Eszopiclone | Dabrafenib | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1407,
24,
1040
]
],
[
[
1407,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1407,
7,
2271
],
[
2271,
57,
1040
]
],
[
[
1407,
21,
28900
],
[
289... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Eszopiclone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)... | Eszopiclone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Eszopiclone (Compound) upregulates STXBP1 (Gene) and STXBP1 (Gene) is downregulated by Dabrafenib (Compound)
Eszopiclone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib ... |
DB00978 | DB01156 | 739 | 593 | [
"DDInter1084",
"DDInter252"
] | Lomefloxacin | Bupropion | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
739,
25,
593
]
],
[
[
739,
6,
7950
],
[
7950,
45,
593
]
],
[
[
739,
21,
28757
],
[
28757,
60,
593
]
],
[
[
739,
23,
1532
],
[
1532,
... | [
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Bupr... | Lomefloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Bupropion (Compound)
Lomefloxacin (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and If... |
DB00374 | DB01324 | 1,061 | 178 | [
"DDInter1852",
"DDInter1490"
] | Treprostinil | Polythiazide | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1061,
24,
178
]
],
[
[
1061,
24,
674
],
[
674,
40,
178
]
],
[
[
1061,
21,
28714
],
[
28714,
60,
178
]
],
[
[
1061,
24,
126
],
[
126,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Treprostinil (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Polythiazide (Compound)
Treprostinil may cause... |
DB00381 | DB06663 | 376 | 1,154 | [
"DDInter79",
"DDInter1398"
] | Amlodipine | Pasireotide | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
376,
24,
1154
]
],
[
[
376,
63,
966
],
[
966,
40,
1154
]
],
[
[
376,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
376,
23,
466
],
[
466,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Amlodipine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Amlodipine may cause a minor int... |
DB01276 | DB14509 | 123 | 1,399 | [
"DDInter706",
"DDInter1081"
] | Exenatide | Lithium carbonate | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
123,
24,
1399
]
],
[
[
123,
63,
874
],
[
874,
23,
1399
]
],
[
[
123,
24,
1574
],
[
1574,
23,
1399
]
],
[
[
123,
63,
820
],
[
820,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea ma... |
DB00026 | DB00262 | 1,184 | 552 | [
"DDInter94",
"DDInter302"
] | Anakinra | Carmustine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Moderate | 1 | [
[
[
1184,
24,
552
]
],
[
[
1184,
24,
377
],
[
377,
63,
552
]
],
[
[
1184,
63,
305
],
[
305,
24,
552
]
],
[
[
1184,
24,
599
],
[
599,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia co... |
DB01069 | DB08938 | 401 | 1,384 | [
"DDInter1533",
"DDInter1112"
] | Promethazine | Magaldrate | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
401,
23,
1384
]
],
[
[
401,
63,
556
],
[
556,
23,
1384
]
],
[
[
401,
74,
1178
],
[
1178,
23,
1384
]
],
[
[
401,
24,
699
],
[
699,
... | [
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic acid"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Promethazine (Compound) resembles Trifluoperazine (Compound) and Promethazine may cause a moderate interac... |
DB00853 | DB06674 | 1,686 | 908 | [
"DDInter1762",
"DDInter837"
] | Temozolomide | Golimumab | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1686,
25,
908
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
908
]
],
[
[
1686,
24,
200
],
[
200,
63,
908
]
],
[
[
1686,
24,
1136
],
[
1136,
... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and C... |
DB00321 | DB00342 | 21 | 1,181 | [
"DDInter78",
"DDInter1770"
] | Amitriptyline | Terfenadine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Moderate | 1 | [
[
[
21,
24,
1181
]
],
[
[
21,
23,
112
],
[
112,
62,
1181
]
],
[
[
21,
24,
1387
],
[
1387,
62,
1181
]
],
[
[
21,
24,
1520
],
[
1520,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
]
],
[
[
"Amitriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Amitriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Terfenadine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Terbinafine ... |
DB00468 | DB01110 | 1,424 | 86 | [
"DDInter1557",
"DDInter1209"
] | Quinine | Miconazole | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
1424,
24,
86
]
],
[
[
1424,
6,
6365
],
[
6365,
45,
86
]
],
[
[
1424,
21,
29122
],
[
29122,
60,
86
]
],
[
[
1424,
25,
318
],
[
318,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Miconazole (Compound)
Quinine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Quinine may lead to a major life threatening interaction when taken with Escitalopram and Esci... |
DB00563 | DB08901 | 663 | 1,468 | [
"DDInter1174",
"DDInter1492"
] | Methotrexate | Ponatinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
663,
24,
1468
]
],
[
[
663,
24,
478
],
[
478,
24,
1468
]
],
[
[
663,
6,
17404
],
[
17404,
45,
1468
]
],
[
[
663,
7,
7478
],
[
7478,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Methotrexate (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ponatinib (Compound)
Methotrexate (Compou... |
DB00011 | DB00363 | 1,451 | 695 | [
"DDInter944",
"DDInter419"
] | Interferon alfa-n1 | Clozapine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
1451,
25,
695
]
],
[
[
1451,
24,
112
],
[
112,
62,
695
]
],
[
[
1451,
24,
1503
],
[
1503,
63,
695
]
],
[
[
1451,
24,
1480
],
[
1480,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clozapine
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Li... |
DB00424 | DB00497 | 19 | 828 | [
"DDInter896",
"DDInter1366"
] | Hyoscyamine | Oxycodone | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Moderate | 1 | [
[
[
19,
24,
828
]
],
[
[
19,
63,
421
],
[
421,
1,
828
]
],
[
[
19,
24,
314
],
[
314,
1,
828
]
],
[
[
19,
24,
560
],
[
560,
40,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxycodone (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine (Compound) resembles Oxycodone (Comp... |
DB00477 | DB08881 | 216 | 868 | [
"DDInter363",
"DDInter1925"
] | Chlorpromazine | Vemurafenib | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
216,
25,
868
]
],
[
[
216,
6,
8374
],
[
8374,
45,
868
]
],
[
[
216,
7,
2703
],
[
2703,
46,
868
]
],
[
[
216,
7,
6886
],
[
6886,
... | [
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Chlorpromazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Chlorpromazine (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Vemurafenib (Compound)
Chlorpromazine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
C... |
DB00222 | DB00717 | 245 | 1,197 | [
"DDInter825",
"DDInter1312"
] | Glimepiride | Norethisterone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Moderate | 1 | [
[
[
245,
24,
1197
]
],
[
[
245,
24,
890
],
[
890,
1,
1197
]
],
[
[
245,
24,
1687
],
[
1687,
40,
1197
]
],
[
[
245,
21,
28751
],
[
28751,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Norethisterone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol and Stanozolol (Compound) resembles Norethisterone (Co... |
DB00682 | DB01357 | 126 | 890 | [
"DDInter1951",
"DDInter1160"
] | Warfarin | Mestranol | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
126,
24,
890
]
],
[
[
126,
24,
35
],
[
35,
40,
890
]
],
[
[
126,
63,
380
],
[
380,
40,
890
]
],
[
[
126,
25,
1546
],
[
1546,
40,... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[
"... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Mestranol (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Mestran... |
DB00889 | DB01764 | 1,133 | 805 | [
"DDInter840",
"DDInter469"
] | Granisetron | Dalfopristin | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
1133,
24,
805
]
],
[
[
1133,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1133,
25,
222
],
[
222,
23,
805
]
],
[
[
1133,
63,
1101
],
[
1101,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Granisetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Granisetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Granisetron may cause a mod... |
DB00023 | DB00598 | 305 | 1,523 | [
"DDInter127",
"DDInter1013"
] | Asparaginase Escherichia coli | Labetalol | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
305,
24,
1523
]
],
[
[
305,
24,
935
],
[
935,
1,
1523
]
],
[
[
305,
24,
1274
],
[
1274,
63,
1523
]
],
[
[
305,
24,
578
],
[
578,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Labetalol (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen ma... |
DB01176 | DB09061 | 537 | 1,627 | [
"DDInter453",
"DDInter284"
] | Cyclizine | Cannabidiol | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
537,
24,
1627
]
],
[
[
537,
63,
1594
],
[
1594,
24,
1627
]
],
[
[
537,
24,
516
],
[
516,
24,
1627
]
],
[
[
537,
40,
104
],
[
104,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Lev... |
DB00041 | DB04861 | 1,648 | 1,592 | [
"DDInter38",
"DDInter1271"
] | Aldesleukin | Nebivolol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1648,
24,
1592
]
],
[
[
1648,
24,
1419
],
[
1419,
24,
1592
]
],
[
[
1648,
24,
512
],
[
512,
63,
1592
]
],
[
[
1648,
25,
976
],
[
976,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid and Iopano... |
DB01110 | DB09073 | 86 | 951 | [
"DDInter1209",
"DDInter1379"
] | Miconazole | Palbociclib | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
86,
24,
951
]
],
[
[
86,
23,
907
],
[
907,
62,
951
]
],
[
[
86,
23,
318
],
[
318,
23,
951
]
],
[
[
86,
62,
1230
],
[
1230,
23,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
... | Miconazole may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Miconazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram and Escitalop... |
DB09123 | DB11569 | 1,525 | 1,093 | [
"DDInter546",
"DDInter1003"
] | Dienogest | Ixekizumab | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1525,
24,
1093
]
],
[
[
1525,
63,
1683
],
[
1683,
24,
1093
]
],
[
[
1525,
63,
1057
],
[
1057,
25,
1093
]
],
[
[
1525,
63,
1683
],
[
16... | [
[
[
"Dienogest",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Dienogest",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etaner... |
DB08816 | DB11828 | 578 | 1,406 | [
"DDInter1802",
"DDInter1281"
] | Ticagrelor | Neratinib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
578,
24,
1406
]
],
[
[
578,
23,
1135
],
[
1135,
23,
1406
]
],
[
[
578,
63,
1252
],
[
1252,
24,
1406
]
],
[
[
578,
24,
710
],
[
710,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may caus... |
DB00213 | DB00945 | 837 | 1,479 | [
"DDInter1388",
"DDInter20"
] | Pantoprazole | Acetylsalicylic acid | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Minor | 0 | [
[
[
837,
23,
1479
]
],
[
[
837,
6,
10215
],
[
10215,
45,
1479
]
],
[
[
837,
21,
28931
],
[
28931,
60,
1479
]
],
[
[
837,
1,
379
],
[
379,
... | [
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v... | Pantoprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Acetylsalicylic acid (Compound)
Pantoprazole (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Acetylsalicylic acid (Compound)
Pantoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cau... |
DB00635 | DB13928 | 1,573 | 1,385 | [
"DDInter1515",
"DDInter1660"
] | Prednisone | Semaglutide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1573,
24,
1385
]
],
[
[
1573,
40,
1103
],
[
1103,
23,
1385
]
],
[
[
1573,
64,
839
],
[
839,
24,
1385
]
],
[
[
1573,
24,
637
],
[
637,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor ... | Prednisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Prednisone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbat... |
DB00005 | DB11760 | 1,057 | 119 | [
"DDInter687",
"DDInter1742"
] | Etanercept | Talazoparib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Major | 2 | [
[
[
1057,
25,
119
]
],
[
[
1057,
24,
66
],
[
66,
24,
119
]
],
[
[
1057,
24,
1129
],
[
1129,
63,
119
]
],
[
[
1057,
25,
713
],
[
713,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizuma... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e s... |
DB00477 | DB01377 | 216 | 1,283 | [
"DDInter363",
"DDInter1119"
] | Chlorpromazine | Magnesium oxide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
216,
23,
1283
]
],
[
[
216,
1,
684
],
[
684,
23,
1283
]
],
[
[
216,
24,
167
],
[
167,
23,
1283
]
],
[
[
216,
35,
104
],
[
104,
2... | [
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may ... | Chlorpromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor in... |
DB00468 | DB01001 | 1,424 | 688 | [
"DDInter1557",
"DDInter1632"
] | Quinine | Salbutamol | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1424,
24,
688
]
],
[
[
1424,
24,
455
],
[
455,
24,
688
]
],
[
[
1424,
24,
1148
],
[
1148,
63,
688
]
],
[
[
1424,
6,
8374
],
[
8374,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"S... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenali... |
DB00883 | DB11827 | 426 | 433 | [
"DDInter989",
"DDInter669"
] | Isosorbide dinitrate | Ertugliflozin | A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
426,
24,
433
]
],
[
[
426,
40,
1107
],
[
1107,
24,
433
]
],
[
[
426,
24,
820
],
[
820,
24,
433
]
],
[
[
426,
63,
999
],
[
999,
2... | [
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) resembles {v} (Compound)",
"Isosorbide mononitrate"
],
[
"Isosorbi... | Isosorbide dinitrate (Compound) resembles Isosorbide mononitrate (Compound) and Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimem... |
DB00342 | DB00831 | 1,181 | 1,178 | [
"DDInter1770",
"DDInter1866"
] | Terfenadine | Trifluoperazine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
1181,
24,
1178
]
],
[
[
1181,
25,
695
],
[
695,
40,
1178
]
],
[
[
1181,
24,
216
],
[
216,
40,
1178
]
],
[
[
1181,
24,
1630
],
[
1630,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Cloz... | Terfenadine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Trifluoperazine (Compoun... |
DB00983 | DB04855 | 480 | 540 | [
"DDInter776",
"DDInter602"
] | Formoterol | Dronedarone | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
480,
24,
540
]
],
[
[
480,
63,
347
],
[
347,
40,
540
]
],
[
[
480,
24,
33
],
[
33,
40,
540
]
],
[
[
480,
6,
12523
],
[
12523,
45... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibutilide"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
... |
DB00333 | DB12332 | 576 | 1,619 | [
"DDInter1166",
"DDInter1626"
] | Methadone | Rucaparib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
576,
25,
1619
]
],
[
[
576,
24,
222
],
[
222,
23,
1619
]
],
[
[
576,
40,
307
],
[
307,
23,
1619
]
],
[
[
576,
23,
112
],
[
112,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine"... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Methadone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit cli... |
DB00108 | DB00352 | 1,066 | 482 | [
"DDInter1268",
"DDInter1814"
] | Natalizumab | Tioguanine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Major | 2 | [
[
[
1066,
25,
482
]
],
[
[
1066,
24,
151
],
[
151,
63,
482
]
],
[
[
1066,
64,
66
],
[
66,
24,
482
]
],
[
[
1066,
25,
869
],
[
869,
6... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H... | Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) and Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) may cause a moderate interaction that could exacerba... |
DB00015 | DB00407 | 582 | 202 | [
"DDInter1585",
"DDInter115"
] | Reteplase | Ardeparin | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Major | 2 | [
[
[
582,
25,
202
]
],
[
[
582,
24,
738
],
[
738,
63,
202
]
],
[
[
582,
24,
1595
],
[
1595,
24,
202
]
],
[
[
582,
25,
1564
],
[
1564,
... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ardeparin
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium hi... |
DB00877 | DB06077 | 629 | 879 | [
"DDInter1678",
"DDInter1102"
] | Sirolimus | Lumateperone | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
629,
24,
879
]
],
[
[
629,
24,
214
],
[
214,
63,
879
]
],
[
[
629,
63,
1645
],
[
1645,
24,
879
]
],
[
[
629,
24,
392
],
[
392,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Met... |
DB00888 | DB01181 | 1,001 | 1,532 | [
"DDInter1133",
"DDInter906"
] | Mechlorethamine | Ifosfamide | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1001,
24,
1532
]
],
[
[
1001,
5,
11555
],
[
11555,
44,
1532
]
],
[
[
1001,
54,
19138
],
[
19138,
15,
1532
]
],
[
[
1001,
21,
29209
],
[
... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{... | Mechlorethamine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Mechlorethamine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound)
Mechlorethamine (Compound) ... |
DB00987 | DB08868 | 1,224 | 1,011 | [
"DDInter460",
"DDInter737"
] | Cytarabine | Fingolimod | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1224,
25,
1011
]
],
[
[
1224,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
1224,
24,
242
],
[
242,
63,
1011
]
],
[
[
1224,
24,
1136
],
[
1136,... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Cytarabine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fingoli... | Cytarabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Cytarabine may cau... |
DB00295 | DB00776 | 475 | 1,335 | [
"DDInter1244",
"DDInter1360"
] | Morphine | Oxcarbazepine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
475,
24,
1335
]
],
[
[
475,
24,
1605
],
[
1605,
1,
1335
]
],
[
[
475,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
475,
25,
902
],
[
902,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Oxcarbazepine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacer... |
DB00436 | DB08882 | 323 | 1,281 | [
"DDInter179",
"DDInter1070"
] | Bendroflumethiazide | Linagliptin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
323,
24,
1281
]
],
[
[
323,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
323,
21,
28873
],
[
28873,
60,
1281
]
],
[
[
323,
24,
251
],
[
251,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aloglipt... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Bendroflumethiazide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Linagliptin (Compound)
Bendroflumethiazid... |
DB00641 | DB09292 | 467 | 1,202 | [
"DDInter1675",
"DDInter1630"
] | Simvastatin | Sacubitril | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the FDA after being given the status of priority review for on July 7, 2015. Sacubitril'... | Moderate | 1 | [
[
[
467,
24,
1202
]
],
[
[
467,
25,
760
],
[
760,
24,
1202
]
],
[
[
467,
24,
1033
],
[
1033,
63,
1202
]
],
[
[
467,
24,
14
],
[
14,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacubitril"
]
],
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicist... | Simvastatin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Sacubitril
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause ... |
DB00209 | DB00366 | 352 | 1,594 | [
"DDInter1886",
"DDInter600"
] | Trospium | Doxylamine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
352,
24,
1594
]
],
[
[
352,
24,
662
],
[
662,
63,
1594
]
],
[
[
352,
6,
7992
],
[
7992,
45,
1594
]
],
[
[
352,
21,
28709
],
[
28709,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Trospium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Doxylamine (Compound)
Trospium (Compound... |
DB01177 | DB14409 | 77 | 1,129 | [
"DDInter904",
"DDInter867"
] | Idarubicin | Human adenovirus e serotype 4 strain cl-68578 antigen | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
77,
24,
1129
]
],
[
[
77,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
77,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
77,
63,
134
],
[
134,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Idarubicin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Idarubicin may cause a moderate interaction that could exacerbate diseases when take... |
DB00696 | DB11837 | 826 | 1,297 | [
"DDInter665",
"DDInter1351"
] | Ergotamine | Osilodrostat | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
826,
24,
1297
]
],
[
[
826,
25,
222
],
[
222,
23,
1297
]
],
[
[
826,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
826,
63,
353
],
[
353,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ergotamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Ergotamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a ... |
DB00363 | DB00539 | 695 | 11 | [
"DDInter419",
"DDInter1837"
] | Clozapine | Toremifene | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
695,
25,
11
]
],
[
[
695,
24,
1594
],
[
1594,
40,
11
]
],
[
[
695,
6,
4973
],
[
4973,
45,
11
]
],
[
[
695,
7,
16703
],
[
16703,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Toremifene (Compound)
Clozapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Toremifene (Compound)
Clozapine (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is ... |
DB00261 | DB01242 | 702 | 1,237 | [
"DDInter93",
"DDInter410"
] | Anagrelide | Clomipramine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Major | 2 | [
[
[
702,
25,
1237
]
],
[
[
702,
25,
684
],
[
684,
1,
1237
]
],
[
[
702,
25,
401
],
[
401,
24,
1237
]
],
[
[
702,
25,
820
],
[
820,
6... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
... | Anagrelide may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases... |
DB00439 | DB11986 | 289 | 484 | [
"DDInter341",
"DDInter648"
] | Cerivastatin | Entrectinib | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
289,
24,
484
]
],
[
[
289,
24,
112
],
[
112,
23,
484
]
],
[
[
289,
24,
466
],
[
466,
62,
484
]
],
[
[
289,
24,
322
],
[
322,
24,... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide... |
DB00701 | DB00743 | 1,091 | 808 | [
"DDInter90",
"DDInter792"
] | Amprenavir | Gadobenic acid | Amprenavir is a protease inhibitor used to treat HIV infection. | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Moderate | 1 | [
[
[
1091,
24,
808
]
],
[
[
1091,
21,
28703
],
[
28703,
60,
808
]
],
[
[
1091,
40,
34
],
[
34,
63,
808
]
],
[
[
1091,
64,
134
],
[
134,
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Amprenavir",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is ca... | Amprenavir (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gadobenic acid (Compound)
Amprenavir (Compound) resembles Fosamprenavir (Compound) and Fos
Amprenavir may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction ... |
DB00344 | DB01362 | 1,302 | 497 | [
"DDInter1543",
"DDInter960"
] | Protriptyline | Iohexol | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1302,
25,
497
]
],
[
[
1302,
21,
28787
],
[
28787,
60,
497
]
],
[
[
1302,
24,
999
],
[
999,
25,
497
]
],
[
[
1302,
40,
998
],
[
998,
... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} ... | Protriptyline (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohex... |
DB00069 | DB06688 | 367 | 1,430 | [
"DDInter946",
"DDInter1677"
] | Interferon alfacon-1 | Sipuleucel-T | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
367,
24,
1430
]
],
[
[
367,
24,
869
],
[
869,
24,
1430
]
],
[
[
367,
25,
676
],
[
676,
63,
1430
]
],
[
[
367,
24,
310
],
[
310,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topot... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Upadacitinib and... |
DB01246 | DB04908 | 820 | 1,671 | [
"DDInter45",
"DDInter741"
] | Alimemazine | Flibanserin | A phenothiazine derivative that is used as an antipruritic. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
820,
24,
1671
]
],
[
[
820,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
820,
24,
407
],
[
407,
63,
1671
]
],
[
[
820,
25,
478
],
[
478,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium ma... |
DB00427 | DB01192 | 1,233 | 560 | [
"DDInter1879",
"DDInter1372"
] | Triprolidine | Oxymorphone | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
1233,
24,
560
]
],
[
[
1233,
24,
828
],
[
828,
1,
560
]
],
[
[
1233,
63,
421
],
[
421,
1,
560
]
],
[
[
1233,
6,
12523
],
[
12523,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxymorphone (... |
DB00014 | DB08868 | 521 | 1,011 | [
"DDInter839",
"DDInter737"
] | Goserelin | Fingolimod | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
521,
25,
1011
]
],
[
[
521,
21,
28817
],
[
28817,
60,
1011
]
],
[
[
521,
23,
1247
],
[
1247,
23,
1011
]
],
[
[
521,
24,
144
],
[
144,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {... | Goserelin (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Fingolimod (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when ta... |
DB00346 | DB00927 | 472 | 1,559 | [
"DDInter44",
"DDInter712"
] | Alfuzosin | Famotidine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
472,
24,
1559
]
],
[
[
472,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
472,
24,
286
],
[
286,
62,
1559
]
],
[
[
472,
23,
112
],
[
112,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Alfuzosin",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused b... | Alfuzosin (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken ... |
DB00539 | DB04911 | 11 | 968 | [
"DDInter1837",
"DDInter1347"
] | Toremifene | Oritavancin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Moderate | 1 | [
[
[
11,
24,
968
]
],
[
[
11,
25,
1079
],
[
1079,
1,
968
]
],
[
[
11,
21,
28883
],
[
28883,
60,
968
]
],
[
[
11,
24,
126
],
[
126,
24... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavanci... | Toremifene may lead to a major life threatening interaction when taken with Telavancin and Telavancin (Compound) resembles Oritavancin (Compound)
Toremifene (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Oritavancin (Compound)
Toremifene may cause a moderate interaction that ... |
DB10989 | DB11714 | 496 | 1,316 | [
"DDInter858",
"DDInter610"
] | Hepatitis A Vaccine | Durvalumab | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
496,
24,
1316
]
],
[
[
496,
63,
167
],
[
167,
24,
1316
]
],
[
[
496,
24,
270
],
[
270,
63,
1316
]
],
[
[
496,
63,
976
],
[
976,
... | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocort... | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00030 | DB08822 | 1,685 | 911 | [
"DDInter934",
"DDInter156"
] | Insulin human | Azilsartan medoxomil | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
1685,
24,
911
]
],
[
[
1685,
24,
217
],
[
217,
1,
911
]
],
[
[
1685,
24,
1450
],
[
1450,
63,
911
]
],
[
[
1685,
24,
549
],
[
549,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate ... |
DB00400 | DB09143 | 353 | 313 | [
"DDInter843",
"DDInter1701"
] | Griseofulvin | Sonidegib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
353,
24,
313
]
],
[
[
353,
24,
478
],
[
478,
24,
313
]
],
[
[
353,
24,
1375
],
[
1375,
63,
313
]
],
[
[
353,
62,
1101
],
[
1101,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamu... |
DB00313 | DB09154 | 556 | 1,475 | [
"DDInter1913",
"DDInter1686"
] | Valproic acid | Sodium citrate | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
556,
23,
1475
]
],
[
[
556,
23,
1411
],
[
1411,
23,
1475
]
],
[
[
556,
24,
663
],
[
663,
23,
1475
]
],
[
[
556,
24,
1479
],
[
1479,
... | [
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
],
... | Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.